CBIO
Crescent Biopharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.88
+2.35%Jul 30, 2026, 00:00 UTC
Crescent Biopharma, Inc. reported its financial results for the second quarter of 2026, with zero revenue, a net loss of $24.8 million, and a diluted EPS of -0.74.
Jul 23, 2026, 20:15 UTC
Crescent Biopharma granted equity inducement awards to two new non-executive employees to secure their acceptance of employment.
Source:Jul 14, 2026, 20:01 UTC
Crescent Biopharma announced a proposed underwritten public offering of its ordinary shares and pre-funded warrants.